MedPal AI plc (LSE:MPAL) has taken another significant step towards becoming one of the UK’s most integrated digital healthcare technology companies with the acquisition of eMARx, a specialist provider of electronic medication administration record (eMAR) software for the UK care home sector.
The acquisition adds a crucial software layer to MedPal’s rapidly expanding healthcare ecosystem, allowing the company to connect every stage of the medication journey, from prescription and robotic dispensing through to bedside administration and AI-powered patient support.
Completing the Healthcare Puzzle
Over the past year, MedPal has been steadily building what it describes as a Health OS, a connected digital platform designed to modernise healthcare delivery.
The business already operates:
- NHS distance-selling pharmacies
- The 23,000 sq ft robotic dispensing facility at Sarus Court
- A growing care home pharmacy business
- New Health, its private healthcare clinic
- Juno, its AI-powered healthcare companion
With the addition of eMARx, MedPal now gains the software platform used directly inside care homes, where every medication administered to residents is digitally verified, recorded and monitored.
This creates what management believes is one of the UK’s only fully integrated medication management platforms.
Entering a Large and Growing Market
The UK has approximately 16,500 care homes supporting more than half a million residents, representing a market worth an estimated £27 billion.
Medication management remains one of the most critical operational challenges within the sector.
Care home residents often take multiple prescriptions each month, while medication errors continue to contribute to avoidable hospital admissions and rising NHS costs.
By combining robotic dispensing, digital medication administration and artificial intelligence, MedPal believes it can help care providers improve patient safety while reducing operational complexity.
High-Quality Recurring Revenue
Beyond the strategic value, eMARx also brings an attractive financial profile.
For the year ending March 2026, the business generated:
- £739,000 revenue
- £106,000 profit after tax
- Approximately 82% gross margins
- A largely recurring software subscription model
Recurring software revenues are highly valued by investors due to their predictability, scalability and attractive margins.
Even more encouraging is that eMARx has approximately tripled revenue over the past three years, demonstrating growing market demand for digital medication management solutions.
Cross-Selling Opportunities
Perhaps the most exciting aspect of the acquisition is the opportunity to expand MedPal’s existing services.
eMARx already serves established care home groups including Care UK, together with numerous independent care providers across Britain.
These relationships create a natural pathway for MedPal to introduce additional services including pharmacy supply, robotic dispensing and AI-driven healthcare support.
Likewise, MedPal’s existing pharmacy customers become ideal candidates for adopting the eMARx platform, creating a powerful cross-selling opportunity that could accelerate growth without the need for significant additional customer acquisition costs.
A Scalable Platform
The acquisition also strengthens utilisation of MedPal’s recently developed robotic dispensing infrastructure.
Management has previously highlighted that Sarus Court was built with significant spare capacity.
By integrating eMARx across more care homes, MedPal can drive increasing prescription volumes through its automated pharmacy operations while maintaining high efficiency and scalability.
This creates operational leverage that could become increasingly valuable as the customer base expands.
Strong Alignment
The transaction structure also aligns the interests of the acquired business with MedPal’s future success.
Rather than being a simple cash acquisition, the majority of the consideration includes MedPal shares that are subject to lock-up arrangements.
Importantly, all seven shareholders of eMARx—including five operational team members, become long-term MedPal shareholders, ensuring continuity, expertise and commitment to future growth.
Looking Ahead
For investors, this acquisition appears to represent more than simply adding another business.
It demonstrates continued execution of a clearly defined strategy to build an integrated healthcare technology platform combining AI, pharmacy automation, software and recurring digital services.
Healthcare continues to undergo rapid digital transformation, while increasing pressure on the NHS and an ageing UK population create long-term structural demand for more efficient medication management solutions.
With the addition of eMARx, MedPal has strengthened both its technology offering and its commercial opportunity, positioning itself to pursue nationwide expansion across one of the UK’s largest healthcare markets.
As MedPal continues executing its Health OS strategy, investors will now be watching closely to see how effectively the company converts this expanded platform into accelerated revenue growth, increased recurring income and greater market penetration across Britain’s care home sector.
For more information visit – https://medpal.co/
